| pubmed-article:2294239 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2294239 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:2294239 | lifeskim:mentions | umls-concept:C0023269 | lld:lifeskim |
| pubmed-article:2294239 | lifeskim:mentions | umls-concept:C0005682 | lld:lifeskim |
| pubmed-article:2294239 | lifeskim:mentions | umls-concept:C0024143 | lld:lifeskim |
| pubmed-article:2294239 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:2294239 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2294239 | pubmed:dateCreated | 1990-2-5 | lld:pubmed |
| pubmed-article:2294239 | pubmed:abstractText | We report 2 cases of leiomyosarcoma of the bladder that occurred after long-term cyclophosphamide chemotherapy for lupus nephritis and rheumatoid arthritis. One patient had a tumor at the end of an 11-year course of chemotherapy and 1 approximately 7 years after completing a 7-year course of chemotherapy. Patient 1 underwent left partial cystectomy and patient 2 underwent cystectomy with ileal conduit urinary diversion. In patient 1 the tumor was a typical leiomyosarcoma and patient 2 had a myxoid variant. Both patients were free of disease at 4 months and 3 years, respectively. Whereas previous reports of the carcinogenic effects of cyclophosphamide have been questioned, since the induced tumors occurred in patients being treated for other neoplasms (lymphoproliferative and myeloproliferative disorders), the disease in both of our patients followed cyclophosphamide therapy for nonneoplastic disorders. | lld:pubmed |
| pubmed-article:2294239 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2294239 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2294239 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2294239 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2294239 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2294239 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:2294239 | pubmed:issn | 0022-5347 | lld:pubmed |
| pubmed-article:2294239 | pubmed:author | pubmed-author:MillerG JGJ | lld:pubmed |
| pubmed-article:2294239 | pubmed:author | pubmed-author:WettlauferJ... | lld:pubmed |
| pubmed-article:2294239 | pubmed:author | pubmed-author:ThrasherJ BJB | lld:pubmed |
| pubmed-article:2294239 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2294239 | pubmed:volume | 143 | lld:pubmed |
| pubmed-article:2294239 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2294239 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2294239 | pubmed:pagination | 119-21 | lld:pubmed |
| pubmed-article:2294239 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2294239 | pubmed:meshHeading | pubmed-meshheading:2294239-... | lld:pubmed |
| pubmed-article:2294239 | pubmed:meshHeading | pubmed-meshheading:2294239-... | lld:pubmed |
| pubmed-article:2294239 | pubmed:meshHeading | pubmed-meshheading:2294239-... | lld:pubmed |
| pubmed-article:2294239 | pubmed:meshHeading | pubmed-meshheading:2294239-... | lld:pubmed |
| pubmed-article:2294239 | pubmed:meshHeading | pubmed-meshheading:2294239-... | lld:pubmed |
| pubmed-article:2294239 | pubmed:meshHeading | pubmed-meshheading:2294239-... | lld:pubmed |
| pubmed-article:2294239 | pubmed:meshHeading | pubmed-meshheading:2294239-... | lld:pubmed |
| pubmed-article:2294239 | pubmed:meshHeading | pubmed-meshheading:2294239-... | lld:pubmed |
| pubmed-article:2294239 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2294239 | pubmed:articleTitle | Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis. | lld:pubmed |
| pubmed-article:2294239 | pubmed:affiliation | Department of Surgery, Fitzsimons Army Medical Center, Aurora, Colorado. | lld:pubmed |
| pubmed-article:2294239 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2294239 | pubmed:publicationType | Case Reports | lld:pubmed |
